Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Akeso, Inc. ( (HK:9926) ) is now available.
Akeso, Inc. announced the results of its HARMONi-6 trial, which were presented at the 2025 European Society For Medical Oncology Symposium and published in The Lancet. The trial demonstrated that ivonescimab plus chemotherapy significantly improved progression-free survival in patients with advanced sq-NSCLC compared to tislelizumab plus chemotherapy. The trial results highlight the superior efficacy and safety profile of ivonescimab, reinforcing Akeso’s leadership in oncology and addressing clinical gaps in current treatments.
The most recent analyst rating on (HK:9926) stock is a Hold with a HK$131.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page.
More about Akeso, Inc.
Akeso, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapies, particularly in oncology. The company is known for its work on antibody-based treatments and aims to address unmet medical needs in cancer treatment.
Average Trading Volume: 12,352,242
Technical Sentiment Signal: Buy
Current Market Cap: HK$112.9B
See more data about 9926 stock on TipRanks’ Stock Analysis page.